SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : ARRIS - Another partner -- Ignore unavailable to you. Want to Upgrade?

To: chirodoc who wrote (221)11/9/1997 7:29:00 PM
From: James Silverman  Read Replies (1) | Respond to of 353
 
Cyberken-Henri Termeer is the CEO of GENZ.
As far as John Walker and David Robinson of Ligand are concerned, neither has created much of any shareholder wealth. I define shareholder wealth as what the stock does, not increasing shareholder equity as defined by accounting standards. I'd say its quite a bit too soon before naming them top notch biotech CEO's. Which is not to say that either CEO is inadequate or their stocks won't perform admirably in years to come.



To: chirodoc who wrote (221)11/9/1997 10:08:00 PM
From: CYBERKEN  Read Replies (1) | Respond to of 353
 
Chirodoc::I bought a little of both. The difference seems to have narrowed a little Friday but essentially it's::

SQNA: buy at $10.625, and converts to 1.35 shares of ARRS. ARRS is
14. So 10.625 X 1.35 is 14.35...a 35 cent benefit.

If you are buying in in the next few weeks, you may want to watch that spread, though it probably won't widen that much from here on out.


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News